Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Pacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...

The major workforce overhaul comes a month after parent company Roche deemed the cell and gene therapy firm a financial loss.

The study, published in The Lancet, a team from the Moorfields Eye Hospital and University College London Institute of ...

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of ...

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a ...

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine.

Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies ...